MENU

Eric M. Horwitz, MD, FABS, FASTRO

Eric Horwitz, MD, FABS, FASTRO

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

About

Chair, Radiation Oncology

Professor

Gerald E. Hanks Endowed Chair in Radiation Oncology

Kidney, Bladder, and Prostate Cancer TRDG Member

NCCN, Prostate Cancer Panel Member

Treatment Focus

  • Intensity Modulated Radiation Therapy (IMRT)
  • Stereotactic body Radiation Therapy (SBRT)
  • HDR temporary prostate brachytherapy
  • LDR permanent prostate brachytherapy

Key Awards

Philadelphia Magazine Top Docs 2020
   Radiation Oncology

Treatment Philosophy

In addition to my focus on treating and caring for patients with prostate and bladder cancer, it is my responsibility as Chairman of the Department of Radiation Oncology at Fox Chase; an NCI designated National Comprehensive Cancer Center to promote the mission of the Center to prevail over cancer. Our department's expertise has always focused on developing and integrating sophisticated technology into successful treatment for our cancer patients and I remain committed to continuing and expanding this legacy. However, the successful treatment of a patient is not just based on the technology that is available. Being diagnosed with cancer and receiving treatment is one of the most difficult things that many people will ever face, and it is crucial that we as caregivers do not forget this. Caring for patients as one important part of a multidisciplinary team allows us in the Department of Radiation Oncology to provide the best possible care for our patients.

Chair, Radiation Oncology

Since joining the staff in 1997, Dr. Horwitz's contributions include spearheading the clinical program as it grew exponentially in size and patient volumes. He developed advanced treatment programs using intensity-modulated radiation therapy (IMRT), image-guided radiation therapy and brachytherapy, including high-dose-rate (HDR) brachytherapy for prostate cancer.

As a result, Fox Chase was the first in the northeastern United States to offer HDR implants to men with prostate cancer.

In addition, Dr. Horwitz integrated the use of an MRI treatment simulator into prostate cancer treatment planning for both permanent, low-dose prostate implants and external radiation therapy. Fox Chase was the first in the world to use MRI in radiation treatment planning... Expand

Education and Training

Educational Background

  • Resident, Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
  • MD, Albany Medical College, Albany, NY, 1992
  • BA, History, Chemistry minor, University of Pennsylvania, Philadelphia, PA, 1988

Certifications

  • American Board of Radiology, Radiation Oncology

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • Prostate Cancer Panel
  • American Society of Radiation Oncology (ASTRO)
  • American Brachytherapy Society (ABS)
  • American Board of Radiology (ABR)
  • American Medical Association (AMA)

Honors & Awards

  • Philadelphia Magazine Top Doctors, 2002, 2005-20
  • Best Doctors in America® , 2013-14, 2019-2020, Radiation Oncology
  • Inaugural Fellow, American Brachytherapy Society (ABS), 2017
  • America’s Top Doctors®, 2015-17
  • Newsweek Top Cancer Doctors, 2015
  • Volunteer Service Award, American Board of Radiology, 2014
  • Distinguished Service Award, American Brachytherapy Society, 2010
Patient Stories

John Donahue

Prostate Cancer

John Donahue

Prostate Cancer

John Donahue was concerned about prostate cancer. From the time he had surgery for an enlarged prostate, John was always aware of his PSA (prostate-specific antigen) level (a protein produced by the cells of the prostate gland). Although his levels were within normal range, they were on an upward climb over a period of 3 to 4 years.

Thomas Donnelly

Colorectal Cancer

Thomas Donnelly

Colorectal Cancer

In 2005, Tom Donnelly left his teaching career to start a web development company. "Although it was a great experience, in 2008 a friend who owned an HVAC business asked me to do account management and sales for him," explained Tom. "It was a wonderful opportunity to work for a fantastic company.” Almost immediately chronic fatigue set in which Tom couldn’t explain. Assuming he was working too much, Tom ignored the weakness and fatigue for two years. He was 38 years old, his career was thriving and he was about to begin graduate school.

Pages

  • 1
  • 2
  • of
  • 2
Research Profile

Research Interests

  • Determining outcomes in treatment for prostate cancer patients treated with external beam radiation and brachytherapy
  • Developing image guidance techniques for prostate cancer radiation
  • Developing new bladder preservation techniques to treat patients with muscle invasive bladder cancer
Publications

Selected Publications

Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology:Jco1802158, 2019. PubMed

Martin, J.M., Li, T., Johnson, M.E., Murphy, C.T., Howald, A.G., Smaldone, M.C., Kutikov, A., Chen, D.Y., Viterbo, R., Greenberg, R.E., Uzzo, R.G., Horwitz, E.M. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center.  J Natl Compr Canc Netw  13:  525-30; 2015. PubMed

Horwitz, E.M. and Weinberg, D.S.  Medicare physician payment data: Is this transparency?  Ann. Int. Med.  161(4):  291-292; 2014. PubMed

Horwitz EM. ABS brachytherapy consensus guidelines. Brachytherapy. 11(1):  4-5, 2012. PubMed

Davis BJ, Horwitz EM, Lee WR, Crook, J. M.; Stock, R. G.; Merrick, G. S.; Butler, W. M.; Grimm, P. D.; Stone, N. N.; Potters, L.; Zietman, A. L.; Zelefsky, M. J.  American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy.  Brachytherapy 11(1):6-19, 2012. PubMed

Crook, J.M.; O'Callaghan, C.J.; Duncan, G.; Dearnaley, D.P.; Higano, C.S.; Horwitz, E.M.; Frymire, E.; Malone, S.; Chin, J.; Nabid, A.; Warde, P.; Corbett, T.; Angyalfi, S.; Goldenberg, S.L.; Gospodarowicz, M.K.; Saad, F.; Logue, J.P.; Hall, E.; Schellhammer, P.F.; Ding, K.; Klotz, L.  Intermittent androgen suppression for rising PSA level after radiotherapy.  New England Journal of Medicine 367:  895-903; 2012. PubMed

Rosenthal, S.A.; Bittner, N.H.; Beyer, D.C.; Demanes, D.J.; Goldsmith, B.J.; Horwitz, E.M.; Ibbott, G.S.; Lee, W.R.; Nag, S.; Suh, W.W.; Potters, L.  American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer.  International Journal of Radiation Oncology Biology Physics 79:  335-41; 2011.  PubMed

Horwitz, E.M.  Why External Beam Radiotherapy Is Treatment of Choice for Most Men With Early-stage Nonmetastatic Prostate Cancer.  Urology 73:  470-472; 2009. PubMed

Horwitz, E.M.; Bae, K.; Hanks, G.E.; Porter, A.; Grignon, D.; Brereton, H.; Venkatesan, V.; Lawton, C.A.; Rosenthal, S.A.; Sandler, H.M.; Shipley, W.U.  Ten-Year Follow-Up of RTOG 92-02:  A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer.  Journal of Clinical Oncology 26:  2497-2504; 2008. PubMed

Langer, C.J.; Harris, J.; Horwitz, E.M.; Nicolaou, N.; Kies, M.; Curran, W.J.; Wong, S.J.; Ang, K.K.  Phase II study of paclitaxel, cisplatin in combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck cancer:  Preliminary results of RTOG 99-11.  Journal of Clinical Oncology 25:  4800-4805; 2007. PubMed

Horwitz, E.M.; Levy, L.B.; Thames, H.D.; Kuban, D.A.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L.  The Biochemical And Clinical Significance Of The Post-Treatment PSA Bounce For Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone: A Multi-Institutional Pooled Analysis.  Cancer 1071:  1496-1502; 2006. PubMed

Kuban, D.A.; Levy, L.B.; Potters, L.; Beyer, D.C.; Blasko, J.C.; Moran, B.J.; Ciezki, J.P.; Zietman, A.L.; Zelefsky, M.J.; Pisansky, T.M.; Elshaikh, M.; Horwitz, E.M.  Comparison of biochemical failure definitions for permanent prostate brachytherapy.  International Journal of Radiation Oncology Biology and Physics 65:  1487-1493; 2006. PubMed

Horwitz, E.M.; Thames, H.D.; Kuban, D.A.; Levy, L.B.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L.  Definitions Of Biochemical Failure That Best Predict Clinical Failure In Prostate Cancer Patients Treated With External Beam Radiation Alone - A Multi-Institutional Pooled Analysis.  Journal of Urology 173:797-802; 2005. PubMed

Horwitz, E.M.; Uzzo, R.G.; Hanlon, A.L.; Greenberg, R.E.; Hanks, G.E.; Pollack, A.  Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone.  Journal of Urology 169:  2153-2159; 2003. PubMed

Hanks, G.E.; Hanlon, A.L.; Epstein, B.; Horwitz, E.M.  Dose response in prostate cancer with 8-12 year follow-up.  International Journal of Radiation Oncology Biology and Physics 54:  427-435; 2002. PubMed

Additional Publications

My NCBI

Ratings

142 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.9
  • 4.9
  • 5.0
  • 5.0
  • 4.9

16 PATIENT COMMENTS

  • 5.0
    October 29, 2019
    Made to feel comfortable at all time. Very knowledgeable.
  • 4.5
    October 21, 2019
    Dr. Horwitz's team is 1st class, so far we are very pleased.
  • 5.0
    October 17, 2019
    Very Good!
  • 5.0
    October 15, 2019
    Always a good experience.
  • 5.0
    September 28, 2019
    Dr. Horowitz was unbelievably open and patient in answering all of our questions (my wife and myself).
  • 5.0
    September 26, 2019
    Dr Horwitz and his staff and support personnel are very caring and exceptionally competent.
  • 5.0
    September 24, 2019
    Very good experience.
  • 5.0
    September 18, 2019
    Dr. Horwitz is very patient& kind. He answers all my questions & gives me all the time I need. He is excellent!
  • 5.0
    September 16, 2019
    Entire process was extremely professional.
  • 5.0
    September 16, 2019
    Dr. Horwitz was the best he could be as a doctor and a person. Outstanding!
  • 5.0
    August 25, 2019
    Provider spends adequate time but I felt rushed.
  • 5.0
    August 05, 2019
    Good experience.
  • 5.0
    July 29, 2019
    Dr. Horwitz explained everything to me and made me feel at ease. My experience at Fox Chase so far has been wonderful and I feel I am in the best of hands.
  • 5.0
    July 29, 2019
    Excellent visit.
  • 5.0
    July 19, 2019
    I was actually (happily) surprised at the amount of time, as well as the information, the doctor and his staff provided. I expected to see him less than 15 minutes.
  • 5.0
    May 29, 2019
    Thought appointment helped me to make my treatment decision.
LOAD MORE

Connect with Fox Chase